Amarantus BioScience Holdings Inc. is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, such as retinitis pigmentosa, Parkinson's disease, Alzheimer's disease, traumatic brain injury and other human diseases. The company has an exclusive worldwide license to the Lymphocyte Proliferation test for Alzheimer's disease, owns the intellectual property rights to the therapeutic protein mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for various protein folding-related medical conditions. Amarantus also owns intellectual property rights for the discovery of neurotrophic factors (PhenoGuard).
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Due to permission requirements, not all quotes are shown.
Amarantus BioScience Holdings Inc. Content
Back to Top